How Common is Microscopic Haematuria?

How Common is Microscopic Haematuria?

Very. While the text-book average is often cited as 5–10%, the prevalence of microscopic haematuria (MH) is highly variable depending on how “healthy” or “screened” a population is.

Many of these patients do not need investigating – and have no significant urinary tract disease. This article will help you decide who needs investigating.

• General Prevalence: Studies of healthy volunteers show a range from 2.4% to 31.1%.

• Clinical Significance: For many, a small amount of blood (defined as >5 red blood cells per high-power field) is a “physiological” baseline rather than a sign of disease.

• Referral Impact: Haematuria remains the “bread and butter” of urology, accounting for over 20-25% of all urological referrals.

2. Categorising the Causes: Surgical vs. Medical

When blood is detected, clinicians must distinguish between “surgical” (structural/urological) and “medical” (nephrological) origins.

Surgical (Urological) Causes

These typically involve the “plumbing” of the urinary tract and may require procedural intervention:

• Malignancy (~3%): Includes bladder, kidney, and ureteral cancers.

• Infection: UTIs, prostatitis, or urethritis (the most common transient causes).

• Calculi (Stones): Kidney or bladder stones can irritate the lining of the tract.

• Prostatic Issues: Benign Prostatic Hyperplasia (BPH) is a leading cause in older men.

• Anatomical: Congenital abnormalities or acquired strictures.

Medical (Nephrological) Causes

These involve the kidney’s filtration system (the glomerulus) and often present with other markers like proteinuria:

• Glomerulonephritis: Such as IgA Nephropathy or Post-streptococcal GN.

• CKD Indicators: Chronic tubulointerstitial disease.

• Thin Basement Membrane Disease: A benign, often familial condition where the kidney filter is simply “leaky.”

3. The 2025 Risk-Stratification Model

Modern medicine has shifted away from “testing everyone” to a risk-based approach to avoid the harms of over-investigation (radiation, invasive scopes, and high costs).

The 2025 AUA/SUFU Guidelines now categorise patients into three tiers:

4. Why “More Testing” Isn’t Always Better

The evaluation of MH involves a delicate balance. While we want to catch the 3% of cancers, the other 97% face potential harms:

• Procedural Risk: Cystoscopy (inserting a camera) can cause discomfort or UTIs.

• Radiation Exposure: CT Urograms involve significant radiation.

• False Positives: Leading to “incidentalomas”—findings that aren’t dangerous but lead to more unnecessary surgeries.

• Guideline Adherence: Historically, adherence to these rules has been poor, but the 2025 updates emphasise Shared Decision Making (SDM), allowing patients in the low and intermediate groups to weigh the risks of a “missed” diagnosis against the harms of the workup.

Key takeaway: If you are “Low Risk,” a single positive test might be a fluke. If you are “High Risk,” or have ever seen visible blood (Gross Haematuria), the risk of cancer jumps significantly, and a full workup is mandatory.